exposures, and diet. NHANES data are used to establish the norms for the general population against which health care providers can compare such patient characteristics as height, weight, and nutrient levels in the blood. Data from NHANES can be compared to those from previous surveys to monitor changes in the health of the U.S. population. NHANES will also establish a national probability sample of genetic material for future genetic research for susceptibility to disease.

Users of NHANES data include Congress; the World Health Organization; Federal agencies such as NIH, EPA, and USDA; private groups such as the American Heart Association; schools of public health; private businesses; individual practitioners; and administrators. NHANES data are used to establish, monitor, and evaluate long-term national health objectives, food fortification policies, programs to limit environmental exposures, immunization guidelines and health education and disease prevention programs. There is no cost to the respondent.

Burden category	Number of respondents between 12/00–12/02	Number of responses/ respondent	Avg. burden per response (in hours)	Total burden (hours)
1. Screening interview only	40,000	1	10/60	6,680
2. Screeners and family interviews only	2,000	1	26/60	868
3. Screeners, family, and SP interviews only	3,000	1	1 6/60	3,303
4. Screener, household, and SP interviews and primary MEC exam only	14,800	1	6 40/60	98,686
5. Screener, household, and SP interviews, primary MEC exam and full MEC replicate exam	740	1	11 40/60	8,634
6. Screener, household, and SP interviews, MEC exam and dietary replicate interview only (5% + optional 15%)	2,960	1	9 1/60	26,693
7. Home exam	200	1	2 36/60	521
8. Telephone follow-up of elderly—option	3,500	1	15/60	875
Total				146,260

Dated: March 20, 2000.

Charles Gollmar,

Acting Associate Director for Policy, Planning, and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–7412 Filed 3–24–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for the remainder of 2000.

At the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. The IOM recommended that the agency publish an annual tentative schedule of its meetings in the **Federal Register**. In response to that recommendation, FDA is publishing its annual tentative scheduled meetings for the remainder of 2000.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4820.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report, the IOM recommended that FDA adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**. FDA has implemented this recommendation. A tentative schedule of forthcoming meetings will be published annually in the **Federal Register**. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. The schedule is tentative and amendments to this notice will not be published in the **Federal Register**. FDA will, however, publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, announcing the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for the remainder of 2000:

Committee Names	Dates of Meetings
OFFICE OF THE COMMISSIONER	
Science Board to the Food and Drug Administration	April 21
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH	
Allergenic Products Advisory Committee	October 24
Biological Response Modifiers Advisory Committee	March 20–21, October 19–20
Blood Products Advisory Committee	March 16–17, June 15–16, September 14–15, December 14–15
Transmissible Spongiform Encephalopathies Advisory Committee	November 2–3
Vaccines and Related Biological Products Advisory Committee	May 11–12, July 27–28, September 21–22, November 2–3
CENTER FOR DRUG EVALUATION AND RESEARCH	
Advisory Committee for Pharmaceutical Science	April 26, May 15–16, November 2–3
Advisory Committee for Reproductive Health Drugs	March 28–29, April 10, May 4–5
Anesthetic and Life Support Drugs Advisory Committee	November 6–7

Committee Names	Dates of Meetings
Anti-Infective Drugs Advisory Committee	March 24, September 11–12
Antiviral Drugs Advisory Committee	July 20–21
Arthritis Advisory Committee	April 11, June 8–9, September 11–12, November 9–10
Cardiovascular and Renal Drugs Advisory Committee	May 1–2, July 20–21, October 19–20
Dermatologic and Ophthalmic Drugs Advisory Committee	May 4–5
Drug Abuse Advisory Committee	October 19–20
Endocrinologic and Metabolic Drugs Advisory Committee	May 18–19, July 13–14, October 5–6, December 7–8
Gastrointestinal Drugs Advisory Committee	April 12
Medical Imaging Drugs Advisory Committee	May 22–23, October 30–31
Nonprescription Drugs Advisory Committee	June 22–23, July 13–14, October 19–20, December 7–8
Oncologic Drugs Advisory Committee	March 16–17, June 5–6
Peripheral and Central Nervous System Drugs Advisory Committee	October 26
Pharmacy Compounding Advisory Committee	May 15–16
Psychopharmacologic Drugs Advisory Committee	June 28–29, November 2–3
Pulmonary-Allergy Drugs Advisory Committee	November 6–7
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION	
Food Advisory Committee	September 14–15
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH	
Device Good Manufacturing Practice Advisory Committee	No meetings planned
Medical Devices Advisory Committee	
Anesthesiology and Respiratory Therapy Devices Panel	May 25–26, September 7–8, November 2–3
Circulatory System Devices Panel	May 2–3, September 25–26
Clinical Chemistry and Clinical Toxicology Devices Panel	March 24, June 29–30, September 14–15, December 14–15
Dental Products Panel	April 6–7, May 23–24, July 18–19, October 3–4
Ear, Nose, and Throat Devices Panel	May 26, June 23, July 20–21, September 22
Gastroenterology-Urology Devices Panel	April 13–14, August 31–September 1, November 30–December 1
General and Plastic Surgery Devices Panel	June 12–13, September 11–12, December 4–5
General Hospital and Personal Use Devices Panel	May 1–2, August 7–8, November 6–7
Hematology and Pathology Devices Panel	June 12, August 8, November 7
Immunology Devices Panel	June 16, September 15, December 8
Medical Devices Dispute Resolution Panel	To be determined
Microbiology Devices Panel	June 21–22, November 16–17
Molecular and Clinical Genetics Panel	June 23, September 15, December 15
Neurological Devices Panel	March 31, May 11–12, August 17–18, November 16–17
Obstetrics-Gynecology Devices Panel	April 10–11, July 24–25, October 9–10
Ophthalmic Devices Panel	March 17, May 11–12, July 27–28, September 21–22, November 8–9
Orthopaedic and Rehabilitation Devices Panel	March 18, May 4–5, August 24–25, November 16–17
Radiological Devices Panel	May 15, August 14, November 6
National Mammography Quality Assurance Advisory Committee	July 10, December 11
Technical Electronic Product Radiation Safety Standards Committee	June 21–22
CENTER FOR VETERINARY MEDICINE	
Veterinary Medicine Advisory Committee	September 15
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH	
Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants	No meetings planned
Science Board to the National Center for Toxicological Research	May 1–2

Dated: March 17, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–7429 Filed 3–24–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Research, Purification, and Further Development of a Factor(s) That Inhibits Human Immunodeficiency Virus (HIV) Replication

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute (NCI) seeks a Cooperative Research and Development Agreement (CRADA) Collaborator to aid NCI in the further characterization and commercial development of a factor(s) that inhibits the replication of the Human Immunodeficiency Virus (HIV). NCI recently discovered that leukocytes stimulated with infectious or ultraviolet-inactivated influenza A virus produce a factor(s) that inhibits the replication of both CCR5- and CXCR4-tropic HIV–1 viral isolates. The factor(s) inhibits replication of the virus after

The National Cancer Institute's Experimental Immunology Branch has identified a factor that is produced by leukocytes when exposed to influenza virus which inhibits HIV replication.